Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies

Bone Marrow Transplantation volume 34, pages 1039–1045 (2004)Cite this article

Summary:

The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m2 over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30–55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6 U, range 1–23), and all received platelets (median 4 U, range 1–27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29%, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58%. We conclude that this regimen is feasible and well tolerated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Armitage JO . Bone marrow transplantation. N Engl J Med 1994; 330: 827–838.

    Article  CAS  Google Scholar 

  2. Frassoni F, Labopin M, Gluckman E et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time – a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996; 17: 13–18.

    CAS  Google Scholar 

  3. Ringden O, Horowitz MM, Gale RP et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993; 270: 57–60.

    Article  CAS  Google Scholar 

  4. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    CAS  Google Scholar 

  5. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    Article  CAS  Google Scholar 

  6. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  Google Scholar 

  7. Sharabi Y, Sachs DH . Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169: 493–502.

    Article  CAS  Google Scholar 

  8. Champlin R, Khouri I, Shimoni A et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29.

    Article  CAS  Google Scholar 

  9. Pawson R, Potter MN, Theocharous P et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG+/− Ida) and second allogeneic stem cell transplant. Br J Haematol 2001; 115: 622–629.

    Article  CAS  Google Scholar 

  10. Alessandrino EP, Bernasconi P, Caldera D et al. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 607–612.

    Article  CAS  Google Scholar 

  11. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.

    Article  CAS  Google Scholar 

  12. Raiola AM, Van Lint MT, Lamparelli T et al. Reduced intensity thiotepa–cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 2000; 109: 716–721.

    Article  CAS  Google Scholar 

  13. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

    Article  CAS  Google Scholar 

  14. Corradini P, Tarella C, Olivieri A et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75–82.

    Article  CAS  Google Scholar 

  15. Alessandrino EP, Bernasconi P, Colombo AA et al. Thiotepa and fludarabine (TT–FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. Ann Hematol 2001; 80: 521–524.

    Article  CAS  Google Scholar 

  16. Wolff SN, Herzig RH, Fay JW et al. High-dose N,N′,N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990; 17: 2–6.

    CAS  Google Scholar 

  17. Alidina A, Lawrence D, Ford LA et al. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Biol Blood Marrow Transplant 1999; 5: 322–327.

    Article  CAS  Google Scholar 

  18. Bernasconi P, Cavigliano PM, Genini E et al. Assessment of chimerism in sex-mismatched allogeneic bone marrrow transplants (allo-BMT) by in situ hybridization and cytogenetics. Is host cell percentage predictive of relapse? Leukemia 1997; 11: 1989–1990.

    CAS  PubMed  Google Scholar 

  19. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  Google Scholar 

  20. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  21. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  22. Martino R, Giralt S, Caballero MD et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003; 88: 555–560.

    PubMed  Google Scholar 

  23. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702–3709.

    CAS  Google Scholar 

  24. Casper J, Knauf W, Kiefer T et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725–731.

    Article  CAS  Google Scholar 

  25. Nagler A, Slavin S, Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021–1028.

    Article  CAS  Google Scholar 

  26. Holland HK, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156–1164.

    Article  CAS  Google Scholar 

  27. Storek J, Dawson MA, Storer B et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380–3389.

    Article  CAS  Google Scholar 

  28. Jiang YZ, Barrett AJ, Goldman JM et al. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1997; 74: 1–6.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to the nursing team of the BMT Unit of our Institution for the attention given to our patients.

Author information

Authors and Affiliations

  1. Division of Haematology, Bone Marrow Transplantation Unit, IRCCS Policlinico San Matteo, Pavia, Italy

    E P Alessandrino, P Bernasconi, A A Colombo, D Caldera, L Malcovati, D Troletti, L Vanelli, M Varettoni, F Montanari & M Lazzarino

Authors
  1. E P Alessandrino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Bernasconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A A Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Caldera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Malcovati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Troletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Vanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Varettoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Montanari
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Lazzarino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E P Alessandrino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alessandrino, E., Bernasconi, P., Colombo, A. et al. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplant 34, 1039–1045 (2004). https://doi.org/10.1038/sj.bmt.1704717

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704717

Keywords

This article is cited by

Search

Advanced search

Quick links